CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
65.71
0.91%
Market Trading Hours* (UTC) Opens on Wednesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.15
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 65.12
Open 64.39
1-Year Change 0.45%
Day's Range 64.39 - 66.02
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 22, 2024 65.12 -0.81 -1.23% 65.93 65.93 64.19
Jul 19, 2024 65.80 0.59 0.90% 65.21 66.03 64.84
Jul 18, 2024 65.29 0.29 0.45% 65.00 66.70 64.34
Jul 17, 2024 65.24 2.26 3.59% 62.98 65.28 62.98
Jul 16, 2024 63.90 0.18 0.28% 63.72 64.23 63.31
Jul 15, 2024 64.15 0.95 1.50% 63.20 64.53 63.01
Jul 12, 2024 63.57 1.25 2.01% 62.32 63.86 62.08
Jul 11, 2024 62.23 2.25 3.75% 59.98 62.57 59.98
Jul 10, 2024 60.66 -0.19 -0.31% 60.85 60.88 59.58
Jul 9, 2024 60.63 2.65 4.57% 57.98 60.84 57.83
Jul 8, 2024 57.98 0.81 1.42% 57.17 58.55 56.98
Jul 5, 2024 57.25 0.14 0.25% 57.11 57.45 56.67
Jul 3, 2024 57.41 -1.36 -2.31% 58.77 59.07 57.40
Jul 2, 2024 58.98 0.43 0.73% 58.55 60.38 58.55
Jul 1, 2024 60.79 0.73 1.22% 60.06 61.87 60.06
Jun 28, 2024 60.52 -0.35 -0.57% 60.87 61.14 59.95
Jun 27, 2024 61.28 -0.30 -0.49% 61.58 61.61 60.73
Jun 26, 2024 61.68 -0.91 -1.45% 62.59 62.61 61.52
Jun 25, 2024 63.04 -0.41 -0.65% 63.45 63.67 63.01
Jun 24, 2024 63.68 0.42 0.66% 63.26 64.03 62.49

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Incyte Company profile

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares

Industry: Biopharmaceuticals

1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US

People also watch

XRP/USD

0.60 Price
-3.390% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

65,888.80 Price
-3.370% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,409.03 Price
+0.520% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 21:00 (UTC)
Spread 0.30

ETH/USD

3,475.70 Price
-0.480% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading